Savara/$SVRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Savara
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Ticker
$SVRA
Sector
Primary listing
Employees
70
Headquarters
Website
Savara Metrics
BasicAdvanced
$1.4bn
-
-$0.56
0.28
-
Price and volume
Market cap
$1.4bn
Beta
0.28
52-week high
$7.01
52-week low
$1.98
Average daily volume
1.4m
Financial strength
Current ratio
13.467
Quick ratio
13.205
Long term debt to equity
17.08
Total debt to equity
17.105
Profitability
EBITDA (TTM)
-133.168
Management effectiveness
Return on assets (TTM)
-40.53%
Return on equity (TTM)
-79.95%
Valuation
Price to book
7.68
Price to tangible book (TTM)
8.21
Price to free cash flow (TTM)
-11.544
Free cash flow yield (TTM)
-8.66%
Free cash flow per share (TTM)
-0.462
Growth
Earnings per share change (TTM)
13.01%
3-year earnings per share growth (CAGR)
28.33%
What the Analysts think about Savara
Analyst ratings (Buy, Hold, Sell) for Savara stock.
Savara Financial Performance
Revenues and expenses
Savara Earnings Performance
Company profitability
Savara News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs